REPLICEL LIFE SCIENCES INC. | CIK:0001205059 | 3

  • Filed: 5/11/2018
  • Entity registrant name: REPLICEL LIFE SCIENCES INC. (CIK: 0001205059)
  • Generator: Compliance Xpressware
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1205059/000106299318002112/0001062993-18-002112-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1205059/000106299318002112/repcf-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001205059
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory

      k)

    Leased assets

         
       

    Where substantially all of the risks and rewards incidental to ownership of a leased asset have been transferred to the Company (a "finance lease"), the asset is treated as if it had been purchased outright. The amount initially recognised as an asset is the lower of the fair value of the leased property and the present value of the minimum lease payments payable over the term of the lease. The corresponding lease commitment is shown as a liability. Lease payments are analysed between capital and interest. The interest element is charged to the consolidated statement of comprehensive income over the period of the lease and is calculated so that it represents a constant proportion of the lease liability. The capital element reduces the balance owed to the lessor.


       

    Where substantially all of the risks and rewards incidental to ownership are not transferred to the Company (an "operating lease"), the total rentals payable under the lease are charged to the consolidated statement of comprehensive income on a straight-line basis over the lease term. The aggregate benefit of lease incentives is recognized as a reduction of the rental expense over the lease term on a straight-line basis.